Nanjing King-Friend Biochemical Pharmaceutical: Net profit for H1 of 2021 about 556 million yuan, up 36% YoY

NBD AI Bulletin - Nanjing King-Friend Biochemical Pharmaceutical Co Ltd (the Company, SH 603707, close price: 30.62 yuan) released the results for the first half of 2021 on August 2. Operating income for the half-year period was about 1.751 billion yuan. Net profit attributable to shareholders of the listed company was about 556 million yuan, an increase of 36% from a year earlier. Basic earnings per share was 0.59 yuan.

The 2020 annual report shows that Nanjing King-Friend Biochemical Pharmaceutical's main business is the pharmaceutical manufacturing industry, accounting for 99.88% of revenue.

Nanjing King-Friend Biochemical Pharmaceutical's general manager and chairman is Tang Yongqun, male, 45 years old, US citizen, master's degree, engineer, senior engineer.

(By Lan Suying)

Disclaimer: The content and data of this article are for reference only and do not constitute investment advice. Please verify before use. Any action you take upon the information on this website is at your own risk.